In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
After finishing at $45.98 in the prior trading day, Bristol-Myers Squibb Co (NYSE: BMY) closed at $43.31, down -5.81%. In other words, the price has decreased by -$5.81 from its previous closing price. On the day, 44.35 million shares were traded. BMY stock price reached its highest trading level at $45.5 during the session, while it also had its lowest trading level at $42.96.
Ratios:
Our goal is to gain a better understanding of BMY by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.48 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.74. For the most recent quarter (mrq), Quick Ratio is recorded 1.17 and its Current Ratio is at 1.28. In the meantime, Its Debt-to-Equity ratio is 2.95 whereas as Long-Term Debt/Eq ratio is at 2.73.
On April 22, 2025, Cantor Fitzgerald started tracking the stock assigning a Neutral rating and target price of $55.
Jefferies Upgraded its Hold to Buy on December 16, 2024, while the target price for the stock was maintained at $70.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 09 ’25 when Hickey Benjamin sold 97 shares for $38.01 per share. The transaction valued at 3,702 led to the insider holds 0 shares of the business.
Hirawat Samit bought 4,250 shares of BMY for $202,215 on Apr 25 ’25. The EVP,Chief Med.Offr.,Drug Dev. now owns 83,513 shares after completing the transaction at $47.58 per share. On Feb 20 ’25, another insider, BOERNER CHRISTOPHER S., who serves as the Chief Executive Officer of the company, bought 2,000 shares for $55.05 each. As a result, the insider paid 110,096 and bolstered with 104,626 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BMY now has a Market Capitalization of 88139317248 and an Enterprise Value of 133121015808. As of this moment, Bristol-Myers’s Price-to-Earnings (P/E) ratio for their current fiscal year is 16.26, and their Forward P/E ratio for the next fiscal year is 7.18. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.23. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.85 while its Price-to-Book (P/B) ratio in mrq is 5.07. Its current Enterprise Value per Revenue stands at 2.795 whereas that against EBITDA is 6.943.
Stock Price History:
The Beta on a monthly basis for BMY is 0.38, which has changed by -0.11195409 over the last 52 weeks, in comparison to a change of 0.18569505 over the same period for the S&P500. Over the past 52 weeks, BMY has reached a high of $63.33, while it has fallen to a 52-week low of $44.00. The 50-Day Moving Average of the stock is -8.96%, while the 200-Day Moving Average is calculated to be -19.28%.
Shares Statistics:
The stock has traded on average 13.91M shares per day over the past 3-months and 13747430 shares per day over the last 10 days, according to various share statistics. A total of 2.04B shares are outstanding, with a floating share count of 2.03B. Insiders hold about 0.08% of the company’s shares, while institutions hold 81.75% stake in the company. Shares short for BMY as of 1752537600 were 38384745 with a Short Ratio of 2.76, compared to 1749772800 on 33614196. Therefore, it implies a Short% of Shares Outstanding of 38384745 and a Short% of Float of 1.8900000000000001.
Dividends & Splits
In the trailing 12 months, BMY’s forward annual dividend rate was 0.0, compared to 2.46 this year. Against a Trailing Annual Dividend Yield of 0.0The stock’s 5-year Average Dividend Yield is 3.63.
